2016 American Society of Clinical Oncology Annual Meeting*

Download All
June 3-7, 2016; Chicago, Illinois
Tiffany Traina, MD, and Sara Hurvitz, MD, review data from key breast cancer presentations at the 2016 American Society of Clinical Oncology Annual Meeting.
Sara Hurvitz, MD, FACP
Tiffany A. Traina, MD

Breast Cancer

Treatment with TaxAC superior to TC in pooled analysis of women with resected high-risk HER2-negative early breast cancer.

Released: June 7, 2016

With 5-year follow-up, local surgery followed by systemic therapy associated with significant improvement in OS vs initial systemic therapy with local therapy for localized progression in patients with MBC at presentation.

Released: June 6, 2016

Phase Ib trial of combination therapy with atezolizumab and nab-paclitaxel showed a safety profile similar to each agent alone and produced durable responses in patients with mTNBC.

Released: June 7, 2016

Phase III investigation of neoadjuvant T-DM1 plus pertuzumab showed a favorable safety profile but lower clinical response rate compared with chemotherapy with trastuzumab plus pertuzumab in HER2-positive early breast cancer.

Released: June 6, 2016

Addition of pertuzumab to trastuzumab and capecitabine improved median OS by 8 months in patients with HER2-positive metastatic breast cancer who previously progressed during/after trastuzumab-based therapy but did not meet the primary endpoint of the study.

Released: June 9, 2016

Palbociclib + letrozole achieved longest improvement in PFS seen to date for frontline treatment of ER+/HER2- advanced breast cancer.

Released: June 14, 2016

Abemaciclib monotherapy was active in patients with heavily pretreated HR+/HER2- MBC and showed no new safety signals.

Released: June 6, 2016

Here are the breast cancer abstracts that I am most interested in hearing about at this year’s ASCO annual meeting.

Sara Hurvitz, MD, FACP Released: May 31, 2016

Sara Hurvitz, MD, FACP, and Tiffany A. Traina, MD, provide their expert analysis of key breast cancer presentations from the 2016 ASCO Annual Meeting in Chicago.

Sara Hurvitz, MD, FACP Tiffany A. Traina, MD Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: August 24, 2016 Expired: No longer available for credit

This study conducted by the Canadian Cancer Trials Group is the first to show that extending aromatase inhibitor therapy beyond 5 years reduces the risk of disease recurrence.

Released: June 7, 2016

In this downloadable slideset, Sara Hurvitz, MD, FACP, and Tiffany A. Traina, MD, review important presentations in breast cancer from the 2016 ASCO meeting in Chicago.

Released: August 16, 2016
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC in collaboration with Postgraduate Institute for Medicine

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Merck & Co., Inc.
Taiho Pharmaceuticals

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings